Cara Therapeutics Inc

-0.47 (-4.00%)
Regulatory, Earnings Announcements

Cara Therapeutics Announces Topline Results From Phase 2 Trial Of Notalgia Paresthetica Treatment

Published: 06/30/2022 11:24 GMT
Cara Therapeutics Inc (CARA) - Cara Therapeutics Announces Positive Topline Results From Komfort Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients With Notalgia Paresthetica.
Cara Therapeutics Inc - Oral Difelikefalin Was Well Tolerated With a Consistent Safety Profile.
Cara Therapeutics Inc - Study Achieved Primary Endpoint of Worst Itch-numeric Rating Scale Score Change From Baseline at Week 8 (p=0.001).
Cara Therapeutics Inc - Onset of Action Seen at Week 1 and Sustained Through Week 8.
Cara Therapeutics Inc - Statistical Significance Achieved on Wi-nrs ≥4-point Responder Analysis at Week 8 (p=0.007).
Revenue is expected to be $9.85 Million
Adjusted EPS is expected to be -$0.41

Next Quarter Revenue Guidance is expected to be $22.67 Million
Next Quarter EPS Guidance is expected to be -$0.24

More details on our Analysts Page.